Immunospec

Core Technology & Specialties

ImmuneSpec provides high-sensitivity immunopeptidomics services using MHC-associated peptide proteomics (MAPPs):

1. Immunogenicity risk assessment – Identify T cell epitopes within therapeutic proteins to evaluate immune safety in preclinical phases.
2. Vaccine antigen discovery – Detect naturally presented pathogen-derived peptides to guide broad-spectrum vaccine design.
3. Immuno‑oncology target validation – Discover and confirm tumor neoantigens via direct MHC‑peptide analyses in tumor tissues